Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,073 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Lin Wei sold 2,073 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the sale, the insider owned 101,366 shares of the company’s stock, valued at $10,083,889.68. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Revolution Medicines Stock Up 1.2%

Shares of RVMD traded up $1.18 during trading hours on Thursday, reaching $99.29. The company’s stock had a trading volume of 1,485,201 shares, compared to its average volume of 2,335,170. The firm has a market cap of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $124.49. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average of $103.58 and a two-hundred day moving average of $76.24.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the business posted ($1.12) EPS. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Neutral Sentiment: Jefferies Financial Group initiated coverage of Revolution Medicines, bringing fresh analyst attention that can boost visibility and trading interest but whose impact depends on the firm’s published rating and price target (not specified in the entry). Jefferies Initiates Coverage
• Negative Sentiment: Insider sale — Xiaolin Wang sold 2,010 shares at an average $99.48 (≈$200k); holding fell ~1.70%, leaving ~116k shares. Multiple officer sales on the same day can be read negatively by the market. SEC Filing
• Negative Sentiment: Insider sale — CFO Jack Anders sold 2,753 shares at $99.48 (≈$274k); his stake declined ~2.15%, now ~125.5k shares. SEC Filing
• Negative Sentiment: Insider sale — COO Margaret A. Horn sold 4,583 shares at $99.48 (≈$456k); her ownership fell ~2.83%, leaving ~157.6k shares. SEC Filing
• Negative Sentiment: Insider sale — Mark A. Goldsmith sold 12,871 shares at $99.48 (≈$1.28M); his holding decreased ~4.44%, leaving ~276.7k shares. Larger absolute size may attract investor attention. SEC Filing
• Negative Sentiment: Insider sale — Stephen Michael Kelsey sold 4,302 shares at $99.48 (≈$428k); his stake fell ~1.44%, leaving ~295.4k shares. SEC Filing
• Negative Sentiment: Insider sale — Lin Wei sold 2,073 shares at $99.48 (≈$206k); her holding declined ~2.00%, leaving ~101.4k shares. SEC Filing

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds have recently bought and sold shares of RVMD. General Atlantic L.P. bought a new position in Revolution Medicines during the third quarter valued at about $115,556,000. Norges Bank bought a new stake in shares of Revolution Medicines during the 4th quarter worth about $195,568,000. Avoro Capital Advisors LLC bought a new stake in shares of Revolution Medicines during the 4th quarter worth about $172,840,000. UBS Group AG increased its holdings in shares of Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after acquiring an additional 1,998,972 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its stake in shares of Revolution Medicines by 321.2% in the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock valued at $160,398,000 after acquiring an additional 1,535,686 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RVMD. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Jefferies Financial Group initiated coverage on Revolution Medicines in a research note on Monday. They issued a “buy” rating for the company. Finally, UBS Group assumed coverage on Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.